Xagrid

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Aktiva substanser:

Anagrelide

Tillgänglig från:

Shire Pharmaceuticals Ireland Limited

ATC-kod:

L01XX35

INN (International namn):

anagrelide

Terapeutisk grupp:

Antineoplastic agents,

Terapiområde:

Thrombocythemia, Essential

Terapeutiska indikationer:

Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or;, a platelet count >1000 x 109/l or;, a history of thrombohaemorrhagic events.,

Produktsammanfattning:

Revision: 33

Bemyndigande status:

Authorised

Tillstånd datum:

2004-11-15